MSI testing Introduction (What it is)
MSI testing is a laboratory test that looks for a pattern of DNA changes called microsatellite instability in a tumor.
It helps clinicians understand how a cancer is behaving at the molecular level.
MSI testing is commonly used in colorectal and endometrial cancers, and it may be used in other tumor types.
Results can inform diagnosis, inherited cancer risk evaluation, and treatment planning.
Why MSI testing used (Purpose / benefits)
MSI testing is used to answer a specific question about tumor biology: is the tumor showing evidence of defective DNA mismatch repair (MMR)? MMR is one of the body’s systems for fixing small DNA copying errors that happen when cells divide. When this repair system is impaired, repetitive DNA regions called microsatellites can become unusually variable in length—this is microsatellite instability (MSI).
In oncology care, this matters for several reasons:
- Tumor classification and prognosis support: MSI status can be one piece of information that helps categorize a tumor and interpret likely behavior. How much it influences prognosis varies by cancer type and stage.
- Identifying possible inherited cancer risk: MSI-high patterns can suggest Lynch syndrome, a hereditary condition linked to pathogenic variants in certain MMR genes. MSI testing itself does not diagnose Lynch syndrome, but it can trigger further evaluation.
- Treatment selection and clinical trial eligibility: Some cancers with MSI-high (MSI-H) or mismatch repair deficiency (dMMR) may respond differently to specific systemic therapies, including certain immunotherapies. Whether this applies depends on the cancer type, stage, prior treatments, and local regulatory approvals.
- Avoiding unnecessary testing: When used thoughtfully, MSI testing can help guide which additional molecular tests or genetic evaluations are most relevant.
Overall, MSI testing aims to reduce uncertainty by adding molecular-level evidence to the clinical picture, alongside imaging, pathology, staging, and patient-specific factors.
Indications (When oncology clinicians use it)
MSI testing may be considered in scenarios such as:
- Newly diagnosed colorectal cancer, especially when universal tumor screening for Lynch syndrome is part of local practice
- Newly diagnosed endometrial cancer, where tumor screening for Lynch syndrome may also be used
- Metastatic or advanced solid tumors where biomarker testing is being used to inform systemic treatment options
- Tumors with histology (microscopic appearance) that can be associated with dMMR/MSI-H, depending on tumor site and pathology findings
- A personal or family history suggestive of a hereditary cancer syndrome, where tumor testing can help prioritize germline (inherited) genetic testing
- Recurrence or progression where updated molecular profiling is being considered and tissue is available
- Clinical trial screening when MSI status is an eligibility criterion
Contraindications / when it’s NOT ideal
MSI testing is generally low risk because it is performed on tissue or blood samples, but it may be less suitable or less informative in situations such as:
- Insufficient or poor-quality tumor sample, such as very small biopsies, low tumor cellularity, or degraded DNA from older specimens
- No confirmed tumor tissue (for example, when the diagnosis is still uncertain and pathology confirmation is pending)
- Cases where MSI status is unlikely to change near-term management, depending on cancer type and stage (varies by clinician and case)
- Situations where another assay is more appropriate for the clinical question, such as targeted mutation testing, broader next-generation sequencing, or specific fusion testing
- Discordant or ambiguous results that require repeat testing or an alternative method (for example, repeating with a different block, using a different platform, or performing MMR immunohistochemistry)
When MSI testing is not feasible from existing tissue, clinicians may consider obtaining a new biopsy or using an alternative testing approach, depending on risks and expected benefit.
How it works (Mechanism / physiology)
MSI testing is a diagnostic biomarker assessment, not a treatment. Its “mechanism” is the detection of a DNA pattern that reflects how the tumor’s repair systems are functioning.
Key biology in plain language
- Microsatellites are short, repetitive DNA sequences spread throughout the genome.
- During cell division, small copying mistakes can occur in these repetitive regions.
- The mismatch repair (MMR) system normally corrects many of these errors.
- If MMR is not working properly (often referred to as dMMR), the microsatellites can become unstable, leading to MSI.
What the result represents
- MSI-H (MSI-high): suggests substantial microsatellite instability, often consistent with mismatch repair deficiency.
- MSS (microsatellite stable) or MSI-L (MSI-low): suggests little or limited microsatellite instability (terminology and reporting may vary by lab and cancer type).
Tissue and organ context
MSI testing evaluates tumor-derived genetic material, typically from:
- Formalin-fixed, paraffin-embedded (FFPE) tumor tissue from a biopsy or surgery specimen
- Less commonly, a blood-based sample may be used for certain platforms, though performance and suitability vary by cancer type and assay
Onset, duration, and reversibility
MSI status is a tumor characteristic, not a temporary effect. It does not have an onset like a medication. It is generally stable over time within a given tumor lineage, but results can vary due to sampling differences, tumor heterogeneity, or technical factors.
MSI testing Procedure overview (How it’s applied)
MSI testing is best understood as part of a broader cancer-care workflow rather than a standalone “procedure.” A typical high-level pathway may look like this:
-
Evaluation/exam
A clinician reviews symptoms, medical history, family history, and performs a physical exam. The goal is to define the clinical question and decide what diagnostic steps are needed. -
Imaging/biopsy/labs
Imaging and laboratory studies may suggest cancer, but pathology from a biopsy or surgical specimen is usually needed to confirm diagnosis and determine tumor type. -
Pathology review
A pathologist evaluates the tumor under a microscope and issues a diagnostic report. This may include tumor grade and other features that guide staging and treatment planning. -
Staging
Clinicians determine the cancer stage using pathology, imaging, and clinical findings. Staging systems vary by cancer type. -
Treatment planning and biomarker selection
The oncology team decides which biomarkers are most relevant. MSI testing may be ordered alone or as part of a broader molecular panel. -
MSI testing performed in the lab
The lab selects tumor-rich areas of the specimen, extracts DNA (or uses other methods depending on the platform), performs the assay, and issues a report. -
Result interpretation and care coordination
Results are interpreted alongside stage, prior treatments, and patient factors. MSI results may also prompt discussion of additional testing (such as MMR immunohistochemistry or germline genetic testing), depending on the case. -
Response assessment and follow-up/survivorship
MSI testing itself is not used to measure treatment response, but it can influence therapy choices that are later monitored with imaging, clinical evaluation, and lab tests.
Types / variations
MSI testing can be performed and reported in different ways. Common variations include:
-
Tumor MSI testing (somatic testing)
Performed on tumor tissue to identify whether the tumor shows microsatellite instability. This is often the first step when MSI status is needed for oncology decision-making. -
Mismatch repair (MMR) immunohistochemistry (IHC) as a related approach
While not MSI testing per se, MMR IHC is frequently discussed alongside MSI because it evaluates the presence/absence of key MMR proteins (commonly MLH1, MSH2, MSH6, PMS2). Labs and clinicians may use MSI testing, MMR IHC, or both, depending on local practice and the clinical question. -
PCR-based MSI testing
Uses polymerase chain reaction to compare specific microsatellite markers and determine whether instability is present. Methods and marker panels can vary by lab. -
Next-generation sequencing (NGS)-based MSI assessment
Some sequencing panels include an MSI algorithm that estimates MSI status from a broader set of genomic data. This may be ordered when multiple biomarkers are needed at once. -
Screening-oriented use vs treatment-selection use
- Screening-oriented: part of tumor screening strategies intended to identify patients who may benefit from evaluation for inherited cancer syndromes (practice varies by institution and cancer type).
-
Treatment-selection: used to help determine whether certain systemic therapies or clinical trials may be appropriate.
-
Solid tumor focus
MSI testing is most established in solid tumors. It is not typically a primary test for hematologic malignancies, though molecular testing strategies in blood cancers can be extensive and are chosen based on disease type.
Pros and cons
Pros:
- Helps characterize tumor biology beyond what can be seen on standard microscopy
- Can support decision-making about additional testing (for example, whether to consider inherited cancer risk evaluation)
- May inform systemic therapy planning in some cancers, including consideration of immunotherapy in selected settings
- Can be performed on existing tumor tissue from a prior biopsy or surgery in many cases
- Often fits into standard pathology and molecular testing workflows
- Can contribute to clinical trial matching when MSI status is relevant
Cons:
- Requires adequate tumor material and quality; small biopsies may be limiting
- Results may be inconclusive or discordant, requiring repeat testing or a different method
- Interpretation can be nuanced and depends on cancer type, stage, and the testing platform
- Turnaround time and access can vary by institution and region
- MSI status alone rarely answers every treatment question; additional biomarkers may still be needed
- An abnormal tumor result can raise questions about inherited risk, which may create uncertainty until further evaluation is completed
Aftercare & longevity
Because MSI testing is a lab assessment, “aftercare” mainly involves communication, interpretation, and follow-through rather than physical recovery—unless a new biopsy was required to obtain tissue.
What can affect how useful the result is over time includes:
- Cancer type and stage: The clinical relevance of MSI status differs across tumor types and early vs advanced disease.
- Tumor biology and heterogeneity: Different tumor areas can sometimes show different features, and small samples may not capture the full picture.
- Quality of the specimen: Fixation, tissue handling, and tumor content can influence test performance.
- Whether testing is paired with related assays: MSI testing may be complemented by MMR IHC, broader sequencing, or germline testing when indicated.
- Treatment course and prior therapies: Over the course of illness, clinicians may update molecular testing strategies; whether retesting is helpful varies by clinician and case.
- Follow-up systems: Clear documentation, genetics referral pathways (when appropriate), and survivorship support can affect whether MSI-related implications are addressed.
From a patient perspective, the “longevity” of MSI testing is often that it becomes part of the permanent pathology and oncology record, helping inform future decisions if the cancer recurs or if additional family-risk evaluation is considered.
Alternatives / comparisons
MSI testing is one of several tools used to understand a tumor. Alternatives or complementary approaches may include:
- MMR immunohistochemistry (IHC) vs MSI testing
- MMR IHC evaluates the presence of MMR proteins in tumor cells.
- MSI testing evaluates DNA instability patterns.
-
They often correlate but are not identical; clinicians may use one, the other, or both depending on context and local protocols.
-
Broader next-generation sequencing (NGS) panels
Instead of a single biomarker test, NGS can assess multiple alterations at once (such as mutations, select rearrangements, and sometimes MSI status). This can be efficient when several biomarkers are relevant, but it may be more resource-intensive and may not be necessary for every case. -
Other immunotherapy-related biomarkers (context-dependent)
Depending on tumor type, clinicians may also consider markers such as tumor mutational burden (TMB) or PD-L1 testing. These tests answer different biological questions and are not interchangeable with MSI testing. -
Germline genetic testing (inherited risk testing)
Germline testing evaluates inherited DNA and can diagnose hereditary cancer syndromes. MSI testing does not directly test inherited DNA, but tumor MSI findings may help identify who should be offered germline evaluation (varies by clinician and case). -
Observation/active surveillance vs biomarker testing
In some early-stage or low-risk situations, clinicians may prioritize standard staging, pathology, and surveillance plans over additional biomarkers. The choice depends on the clinical scenario and whether a biomarker is likely to change management. -
Standard care vs clinical trials
MSI status can be a trial eligibility factor for certain studies. Trial participation depends on many variables, including tumor type, prior therapy, health status, and availability.
MSI testing Common questions (FAQ)
Q: Is MSI testing the same as genetic testing for inherited cancer risk?
MSI testing usually examines the tumor, not the DNA you were born with. It can suggest that mismatch repair is not working normally in the tumor, which sometimes raises the possibility of an inherited condition like Lynch syndrome. Confirming an inherited condition generally requires separate germline genetic testing and counseling.
Q: Will MSI testing hurt or require anesthesia?
MSI testing itself is performed in a laboratory and does not cause pain. If a new biopsy is needed to obtain tumor tissue, the biopsy procedure may involve local anesthesia or sedation depending on the site and approach. The need for a biopsy and how it is done varies by clinician and case.
Q: How long does MSI testing take?
Turnaround time varies by laboratory, testing method, and whether the test is run alone or as part of a larger panel. Results may also take longer if the lab needs additional tissue sections or if repeat testing is required. Your care team typically reviews results once the full pathology and biomarker information is available.
Q: How is MSI testing used to guide treatment?
In some cancers, MSI-H or dMMR status may influence systemic treatment planning and may support consideration of certain immunotherapies or clinical trials. The impact of MSI status on treatment decisions varies by cancer type and stage. Clinicians interpret MSI results alongside pathology, imaging, prior treatments, and overall health.
Q: Are there side effects or risks from MSI testing?
The lab test itself has no direct physical side effects. Risks mainly relate to how the tissue is obtained (for example, biopsy-related bleeding, infection, or discomfort), and those risks depend on the biopsy site and technique. There can also be emotional or practical impacts if results raise the possibility of inherited cancer risk.
Q: What does “MSI-high” mean in plain language?
MSI-high means the tumor shows a pattern of DNA changes suggesting many errors are not being repaired properly. This often aligns with mismatch repair deficiency, although confirmation and interpretation depend on the specific test and context. It is a tumor characteristic that may have implications for additional evaluation and therapy planning.
Q: Can MSI testing be done from blood instead of a tissue biopsy?
Some platforms can estimate MSI status from circulating tumor DNA in blood, but suitability and accuracy can vary by cancer type, tumor burden, and the assay used. Tissue remains a common standard source when available because it allows direct assessment of the tumor and accompanying pathology. Clinicians choose the approach based on feasibility and the clinical question.
Q: How much does MSI testing cost?
Costs vary widely based on the country, hospital system, insurance coverage, and whether the test is performed as a standalone assay or bundled into a larger sequencing panel. There may also be separate costs for biopsy procedures or pathology processing. Many centers have financial counseling resources to help patients understand coverage and out-of-pocket expectations.
Q: Will MSI testing affect my ability to work or do normal activities?
MSI testing performed on existing tissue does not affect day-to-day activities. If a new biopsy is required, activity limits—if any—depend on the biopsy type and location, and your team typically provides procedure-specific instructions. Follow-up is usually focused on discussing results and how they fit into the overall care plan.
Q: Does an MSI-related result have implications for fertility or family members?
MSI testing does not directly assess fertility. However, if tumor results raise concern for an inherited cancer syndrome, germline testing may be discussed, which can have implications for relatives and family planning decisions. These considerations are typically addressed through genetic counseling rather than MSI testing alone.